Table 3. Linear regression analysis for the absolute numbers of different immune cell subsets.
Leukocyte subsets | Predicting variable | p-value | β coefficient | R2 model |
---|---|---|---|---|
Lymphocytes | CMV status | 0.869 | 0.015 | 0.072 |
Gender | 0.046* | −0.176 | ||
Gender*CMV | 0.227 | −0.129 | ||
Age | 0.375 | 0.055 | ||
T cell | CMV status | 0.928 | −0.008 | 0.108 |
Gender | 0.016* | −0.209 | ||
Gender*CMV | 0.124 | −0.162 | ||
Age | 0.422 | 0.049 | ||
CD4 T cell | CMV status | 0.580 | −0.049 | 0.153 |
Gender | 0.015* | −0.206 | ||
Gender*CMV | 0.029* | −0.223 | ||
Age | 0.452 | 0.044 | ||
CD4 naive | CMV status | 0.048* | −0.178 | 0.121 |
Gender | 0.002* | −0.272 | ||
Gender*CMV | 0.652 | −0.047 | ||
Age | 0.547 | 0.036 | ||
CD4 CM T cell | CMV status | 0.820 | 0.021 | 0.102 |
Gender | 0.801 | 0.022 | ||
Gender*CMV | 0.001* | −0.342 | ||
Age | 0.855 | 0.011 | ||
CD4 TemRO | CMV status | 0.135 | 0.138 | 0.074 |
Gender | 0.237 | −0.104 | ||
Gender*CMV | 0.032* | −0.230 | ||
Age | 0.801 | 0.016 | ||
CD4 TemRO late | CMV status | 0.000* | 0.585 | 0.305 |
Gender | 0.612 | 0.039 | ||
Gender*CMV | 0.586 | −0.050 | ||
Age | 0.732 | −0.018 | ||
CD4 TemRA | CMV status | 0.444 | 0.070 | 0.083 |
Gender | 0.003* | −0.263 | ||
Gender*CMV | 0.858 | −0.019 | ||
Age | 0.555 | 0.036 | ||
CD4 TemRA late | CMV status | 0.000* | 0.430 | 0.260 |
Gender | 0.044* | −0.161 | ||
Gender*CMV | 0.403 | 0.080 | ||
Age | 0.485 | 0.039 | ||
TFH | CMV status | 0.342 | 0.089 | 0.053 |
Gender | 0.479 | −0.063 | ||
Gender*CMV | 0.045* | −0.217 | ||
Age | 0.518 | 0.040 | ||
CD8 T-cell | CMV status | 0.440 | 0.072 | 0.038 |
Gender | 0.057 | −0.171 | ||
Gender*CMV | 0.940 | −0.008 | ||
Age | 0.766 | −0.019 | ||
CD8 naive | CMV status | 0.310 | −0.089 | 0.169 |
Gender | 0.000* | −0.340 | ||
Gender*CMV | 0.870 | −0.017 | ||
Age | 0.001* | −0.196 | ||
CD8 CM T cell | CMV status | 0.656 | −0.041 | 0.070 |
Gender | 0.908 | 0.010 | ||
Gender*CMV | 0.029* | −0.235 | ||
Age | 0.254 | 0.071 | ||
CD8 TemRO | CMV status | 0.110 | 0.152 | 0.015 |
Gender | 0.545 | 0.055 | ||
Gender*CMV | 0.114 | −0.175 | ||
Age | 0.712 | 0.023 | ||
CD8 TemRO late | CMV status | 0.000* | 0.585 | 0.305 |
Gender | 0.612 | 0.039 | ||
Gender*CMV | 0.586 | −0.050 | ||
Age | 0.732 | −0.018 | ||
CD8 TemRA | CMV status | 0.025* | 0.206 | 0.089 |
Gender | 0.097 | −0.145 | ||
Gender*CMV | 0.350 | 0.099 | ||
Age | 0.622 | 0.030 | ||
CD8 TemRA late | CMV status | 0.000* | 0.412 | 0.259 |
Gender | 0.132 | −0.119 | ||
Gender*CMV | 0.183 | 0.128 | ||
Age | 0.388 | 0.048 |
Linear (Enter) regression was performed on log-transformed data by using the variables CMV status (0 = seronegative, 1 = seropositive), Gender (0 = female, 1 = male), Gender* CMV status, and Age (years). Bold numbers indicate significant differences within one subset. *p < 0.05. After a multiple testing correction only values with p < 0.0014 are considered significant, which are underlined. The p-value indicates the association with the absolute number of immune cells, the β coefficient indicates the strength of the association, and the R2 explains the strength of the model in predicting the absolute number of immune cells.